Prosperini L - Search Results

1

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A. Prosperini L, et al. Mult Scler. 2015 Nov;21(13):1713-22. doi: 10.1177/1352458515570768. Epub 2015 Feb 19. Mult Scler. 2015. PMID: 25698174

2

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, Antonelli G, Bastianello S, Pozzilli C. Tomassini V, et al. Among authors: prosperini l. J Neurol. 2006 Mar;253(3):287-93. doi: 10.1007/s00415-005-0979-5. Epub 2005 Sep 14. J Neurol. 2006. PMID: 16151600 Clinical Trial.

3

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.

Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Pozzilli C, et al. Among authors: prosperini l. Neurol Sci. 2005 Dec;26 Suppl 4:S174-8. doi: 10.1007/s10072-005-0510-x. Neurol Sci. 2005. PMID: 16388353 Clinical Trial.

4

Interferon after 10 years in patients with multiple sclerosis.

Pozzilli C, Prosperini L, Sbardella E, Paolillo A. Pozzilli C, et al. Among authors: prosperini l. Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. doi: 10.1007/s10072-006-0697-5. Neurol Sci. 2006. PMID: 16998723 Review.

5

Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis.

Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Giovannelli M, et al. Among authors: prosperini l. Clin Rehabil. 2007 Apr;21(4):331-7. doi: 10.1177/0269215507072772. Clin Rehabil. 2007. PMID: 17613573 Clinical Trial.

6

Natalizumab treatment in pediatric multiple sclerosis: a case report.

Borriello G, Prosperini L, Luchetti A, Pozzilli C. Borriello G, et al. Among authors: prosperini l. Eur J Paediatr Neurol. 2009 Jan;13(1):67-71. doi: 10.1016/j.ejpn.2008.01.007. Epub 2008 Apr 11. Eur J Paediatr Neurol. 2009. PMID: 18406645

7

Primary headache and multiple sclerosis: preliminary results of a prospective study.

Villani V, Prosperini L, Ciuffoli A, Pizzolato R, Salvetti M, Pozzilli C, Sette G. Villani V, et al. Among authors: prosperini l. Neurol Sci. 2008 May;29 Suppl 1:S146-8. doi: 10.1007/s10072-008-0908-3. Neurol Sci. 2008. PMID: 18545918

8

Clinical markers of therapeutic response to disease modifying drugs.

Pozzilli C, Prosperini L. Pozzilli C, et al. Among authors: prosperini l. Neurol Sci. 2008 Sep;29 Suppl 2:S211-3. doi: 10.1007/s10072-008-0939-9. Neurol Sci. 2008. PMID: 18690494 Review.

9

Emerging oral drugs for multiple sclerosis.

Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. Gasperini C, et al. Among authors: prosperini l. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465. Expert Opin Emerg Drugs. 2008. PMID: 18764723 Review.

10

MRI for monitoring response to preventive treatment in multiple sclerosis.

Pozzilli C, Petsas N, Prosperini L. Pozzilli C, et al. Among authors: prosperini l. Expert Rev Neurother. 2009 Mar;9(3):305-7. doi: 10.1586/14737175.9.3.305. Expert Rev Neurother. 2009. PMID: 19271936 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters